Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515 http://lobbyingdisclosure.house.gov
Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510 http://www.senate.gov/lobby
LOBBYING REPORT
Lobbying Disclosure Act of 1995 (Section 5)
- All Filers Are Required to Complete This Page
1. Registrant Name Organization/Lobbying Firm Self Employed Individual
ALPINE GROUP, INC.
2. Address
Address1
660 PENNSYLVANIA AVE, SE
Address2
SUITE 201
City
WASHINGTON
State
DC
Zip Code
20003
Country
USA
3. Principal place of business (if different than line 2)
City
State
Zip Code
Country
4a. Contact Name
b. Telephone Number
c. E-mail
Ms.
Jessica Slotman
2025471831
jslotman@alpinegroup.com
5. Senate ID#
1171-87
7. Client Name
Self
Check if client is a state or local government or instrumentality
COUNCIL ON RADIONUCLIDES AND RADIOPHARMACEUTICALS
6. House ID#
317490005
TYPE OF REPORT
8. Year
2012
Q1 (1/1 - 3/31)
Q2 (4/1 - 6/30)
Q3 (7/1 - 9/30)
Q4 (10/1 - 12/31)
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report
Termination Date
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying
13. Organizations
INCOME relating to lobbying activities
for this reporting period was:
EXPENSE relating to lobbying activities
for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more
$
70,000.00
$5,000 or more
$
Provide a good faith estimate, rounded to the nearest
$10,000,
of all lobbying related income from the client (including all
payments to the registrant by any other entity for lobbying
activities on behalf of the client).
14. REPORTING
Check box to indicate expense accounting method. See instructions
for description of options.
Method A.
Reporting amounts using LDA definitions only
Method B.
Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
Method C.
Reporting amounts under section 162(e) of the Internal Revenue Code
Signature
Digitally Signed By: Jessica Slotman, Executive Assistant
Date
01/14/2013
LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.
15. General issue area code ENG
16. Specific lobbying issues
legislation affecting the production of medical isotopes legislation to upgrade security of radiopharmaceutical facilities S.99, American Medical Isotopes Production Act of 2011 H.R. 3276,
17. House(s) of Congress and Federal agencies
Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name
Last Name
Suffix
Covered Official Position (if applicable)
New
James
Massie
19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None
LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of Prescription Drug User Fee Act of 2007, provision affecting PET drugs and medical advisory committees. S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 1483, Drug Safety Enhancement Act of 2011 H.R. 4095, Online Pharmacy Safety Act H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011 S. 296, Preserving Access to Life-Saving Medications Act H.R. 3630, Temporary Payroll Tax Cut Continuation Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 H.R. 5651, Food and Drug Administration Reform Act of 2012 S. 3187, Food and Drug Administration Safety and Innovation Act
17. House(s) of Congress and Federal agencies
Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA),
18. Name of each individual who acted as a lobbyist in this issue area
First Name
Last Name
Suffix
Covered Official Position (if applicable)
New
Courtney
Johnson
Research Asst, House Energy and Commerce Cmte
James
Massie
James
Hawkins
III
Health Policy Advisor, Senate HELP Committee
19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None
LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare reimbursement for of radiopharmaceuticals
17. House(s) of Congress and Federal agencies
Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name
Last Name
Suffix
Covered Official Position (if applicable)
New
Courtney
Johnson
Research Asst, House Energy and Commerce Cmte
James
Massie
James
Hawkins
III
Health Policy Advisor, Senate HELP Committee
19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None
Information Update Page - Complete ONLY where
registration information has changed.
20. Client new address
Address
City
State
Zip Code
Country
21. Client new principal place of business (if different than line 20)
City
State
Zip Code
Country
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer
expected to act as a lobbyist for the client
First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
21
2
22
3
23
4
24
5
25
6
26
7
27
8
28
9
29
10
30
11
31
12
32
13
33
14
34
15
35
16
36
17
37
18
38
19
39
20
40
ISSUE UPDATE
24. General lobbying issue that no longer pertains
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name
Address
Principal Place of Business
(city and state or country)
Street Address
City
State/Province
Zip
Country
RIT Oncology
157 Technology Drive
Irving
CA
92615
USA
City
State
Country
Covidien
675 McDonnell Blvd
St. Louis
MO
63042
USA
City
State
Country
DRAXIMAGE
16751 Transcanada Hwy
Kirkland
QC
H9H 4J4
CAN
City
State
Country
SHINE
8123 Forsythia St.
Middleton
WI
53562
USA
City
State
Country
Eckert & Ziegler Istopes Inc
24937 Avenue Tibbitts
Valencia
CA
91355
USA
City
State
Country
Jazz Pharmaceuticals
1717 Newton Langhorne Road
Langhorne
PA
19047
USA
City
State
Country
International Isotopes
4137 Commerce Circle
Idaho Falls
ID
83401
USA
City
State
Country
Lantheus Medical Imaging
331 Treble Cove Road
North Billerica
MA
01862
USA
City
State
Country
Nordion Inc.
447 March Road
Ottawa
ON
K2K 1X8
CAN
City
State
Country
Cardinal Health, Nuc Pharm Services
7000 Cardinal Place
Dublin
OH
43107
USA
City
State
Country
PerkinElmer Life and Analytical Sci.
549 Albany Street
Boston
MA
02118
USA
City
State
Country
PETNET Solutions, Inc
810 Innovation Drive
Knoxville
TN
37932
USA
City
State
Country
QSA Global, Inc
40 North Avenue
Burlington
MA
01803
USA
City
State
Country
Alseres Pharmaceutical Molecular Im
239 South Street
Hopkinton
MA
01748
USA
City
State
Country
26. Name of each previously reported organization that is no longer affiliated
with the registrant or client
1
11
21
2
12
22
3
13
23
4
14
24
5
15
25
6
16
26
7
17
27
8
18
28
9
19
29
10
20
30
FOREIGN ENTITIES
27. Add the following foreign entities:
Name
Address
Principal place of business
(city and state or country)
Amount of contribution for lobbying activities
Ownership percentage in client
Street Address
City
State/Province
Country
City
State
Country
%
28. Name of each previously reported foreign entity that no longer owns,
or controls, or is affiliated with the registrant, client or affiliated organization